Abstract
Treatment with a combination of pulse methylprednisolone (MP) and an alkylating agent has been reported to induce long-term remission of proteinuria in patients with steroid-resistant nephrotic syndrome (SRNS). We have treated 13 patients with SRNS with a course of pulse MP. There were 8 black patients and 5 white; 10 had a biopsy diagnosis of focal segmental glomerulosclerosis (FSGS) and 3 nil lesion. Initially 5 patients responded and 2 partially responded. Of the responding patients, 5 relapsed while treated with alternate-week MP therapy. Of these relapsing patients, 3 received a second course of MP plus chlorambucil; 2 responded. The patients were observed for a mean of 47 months (range 4–64 months). When last seen only the 3 patients with a biopsy diagnosis of nil lesion were protein free. There were no complications of steroid therapy. Six patients currently have end-stage renal disease and 2 have renal insufficiency. All of the 6 patients with no response to treatment were black. These data suggest that a course of pulse MP therapy alone induces short-term remission of the nephrotic syndrome in some white patients with FSGS, but in almost no blacks. Patients who relapse may respond to retreatment, but addition of an alkylating agent does not appear to induce longterm remission in patients with FSGS.
Similar content being viewed by others
References
Southwest Pediatric Nephrology Study Group (1985) Focal segmental glomerulosclerosis in children with idiopathic nephrotic syndrome. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int 27: 442–449
Habib R (1973) Focal glomerular sclerosis. Kidney Int 4: 355–361
Kohaut EC, Singer DB, Hill LL (1976) The significance of focal glomerular sclerosis in children who have nephrotic syndrome. Am J Clin Pathol 66: 545–550
Tejani A, Nicastri AD, Sen D, Chen CK, Phadke K, Adamson O, Butt KM (1983) Long-term evaluation of children with nephrotic syndrome and focal segmental glomerular sclerosis. Nephron 35: 225–231
Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG (1978) The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 10: 213–218
Mendoza SA, Reznik VM, Griswold WR, Krensky AM, Yorgin PD, Tune BM (1990) Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 4: 303–307
Houser M (1984) Assessment of proteinuria using random urine samples. J Pediatr 104: 849–854
Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am 34: 571–590
Ingulli E, Tejani A (1991) Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr Nephrol 5: 393–397
Rostand SG, Kirk KA, Rusky EA, Pate BA (1982) Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 306: 1276–1282
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Waldo, F.B., Benfield, M.R. & Kohaut, E.C. Methylprednisolone treatment of patients with steroid-resistant nephrotic syndrome. Pediatr Nephrol 6, 503–505 (1992). https://doi.org/10.1007/BF00866483
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00866483